XORTX Therapeutics (XRTX) Assets Average (2021 - 2026)

XORTX Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• Quarterly Assets Average fell 36.41% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 36.41% YoY) and the FY2025 annual result came in at $3.4 million, down 29.12% from the prior year.
• Assets Average was $2.4 million for Q1 2026 at XORTX Therapeutics, down from $2.7 million in the prior quarter.
• Across five years, Assets Average topped out at $16.0 million in Q1 2022 and bottomed at $2.4 million in Q1 2026.
• A 5-year average of $7.3 million and a median of $5.4 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average grew 0.46% — and 2025, when it sank 42.48%.
• XORTX Therapeutics' Assets Average stood at $11.9 million in 2022, then tumbled by 39.36% to $7.2 million in 2023, then sank by 44.99% to $4.0 million in 2024, then slumped by 30.84% to $2.7 million in 2025, then declined by 12.13% to $2.4 million in 2026.
• Business Quant data shows XRTX's Assets Average at $2.4 million in Q1 2026, $2.7 million in Q4 2025, and $2.8 million in Q3 2025.